RetaCalc
Protocol library
SingleNot ApprovedMixedLow confidenceSourced

NAD+

A cellular coenzyme used in heterogeneous infusion and metabolic research. Human evidence does not establish a standard subcutaneous research-vial protocol.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideDaily
Third-party educational schedule for a 500 mg vial

50 mg daily in week 1, 75 mg in week 2 and 100 mg daily in weeks 3-16

The guide uses a subcutaneous route not established by the heterogeneous human infusion literature. It must not be treated as equivalent to monitored intravenous research.

View source

Evidence summary

A cellular coenzyme used in heterogeneous infusion and metabolic research. Human evidence does not establish a standard subcutaneous research-vial protocol.

Protocol basis

The evidence review focuses on directly administered NAD+ and excludes studies that only test oral precursors. Available protocols are heterogeneous and route-specific.

What remains uncertain

Controlled outcome evidence, subcutaneous pharmacokinetics and a validated research-vial schedule remain absent.

Warnings and contraindications

NAD+ is not interchangeable with NAD+ precursors such as NR or NMN.
Intravenous infusion observations do not validate subcutaneous administration.
Stability, compatibility and systemic exposure depend on formulation and route.